Clinical Trials Logo

Treatment Resistant Depression clinical trials

View clinical trials related to Treatment Resistant Depression.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06232291 Enrolling by invitation - Clinical trials for Major Depressive Disorder

Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant Depression

Start date: April 21, 2023
Phase:
Study type: Observational

An observational-comparative study, without interfering with the treatment, based on an operationalized interview.

NCT ID: NCT04971291 Enrolling by invitation - Clinical trials for Major Depressive Disorder

An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients

TARGET
Start date: April 14, 2021
Phase: Phase 2
Study type: Interventional

The TARGET study is an active-controlled evaluation of AXS-05 compared to bupropion in patients with treatment-resistant major depressive disorder (MDD) who are adherent to study drug. Subjects are considered to have treatment-resistant MDD if they have had a historical inadequate response to 1 or 2 prior antidepressant treatments (ADTs) and a prospective inadequate response to treatment with bupropion SR, during the current major depressive episode. The TARGET study will first determine treatment adherence based on analysis of drug concentrations of dextromethorphan (in the AXS-05 group) and bupropion (in the bupropion group), and then evaluate the efficacy of AXS-05 in patients determined to be treatment-adherent. Efficacy data for evaluation of treatment effect will be obtained from assessments made during study AXS-05-301.

NCT ID: NCT03680781 Enrolling by invitation - Clinical trials for Treatment Resistant Depression

Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study

Start date: April 13, 2018
Phase: N/A
Study type: Interventional

This study evaluates the effectiveness of re-treatment using accelerated schedule of intermittent theta-burst stimulation for treatment-resistant depression. This is an open label study.